Other discussed MM biomarkers include soluble mesothelin-related peptides, megakaryocyte potentiating factor, osteopontin, fibulin-3 and high mobility group protein B1 (HMGB1) [7]. This evidence concerns the gene MSLN and Miyoshi myopathy.